AT360006B - Verfahren zur herstellung von neuen thiazolinylbenzimidazolderivaten - Google Patents

Verfahren zur herstellung von neuen thiazolinylbenzimidazolderivaten

Info

Publication number
AT360006B
AT360006B AT636476A AT636476A AT360006B AT 360006 B AT360006 B AT 360006B AT 636476 A AT636476 A AT 636476A AT 636476 A AT636476 A AT 636476A AT 360006 B AT360006 B AT 360006B
Authority
AT
Austria
Prior art keywords
thiazolinylbenzimidazole
derivatives
producing new
producing
new
Prior art date
Application number
AT636476A
Other languages
English (en)
Other versions
ATA636476A (de
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ATA636476A publication Critical patent/ATA636476A/de
Application granted granted Critical
Publication of AT360006B publication Critical patent/AT360006B/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT636476A 1975-10-28 1976-08-26 Verfahren zur herstellung von neuen thiazolinylbenzimidazolderivaten AT360006B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62601475A 1975-10-28 1975-10-28
US06/002,836 US4216313A (en) 1975-10-28 1979-01-12 Antiviral thiazinyl benzimidazoles

Publications (2)

Publication Number Publication Date
ATA636476A ATA636476A (de) 1980-05-15
AT360006B true AT360006B (de) 1980-12-10

Family

ID=26670950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT636476A AT360006B (de) 1975-10-28 1976-08-26 Verfahren zur herstellung von neuen thiazolinylbenzimidazolderivaten

Country Status (11)

Country Link
US (2) US4150028A (de)
JP (1) JPS5253861A (de)
AT (1) AT360006B (de)
AU (1) AU509008B2 (de)
BE (1) BE845642A (de)
CA (1) CA1076582A (de)
CH (1) CH629203A5 (de)
DE (1) DE2638553C2 (de)
FR (1) FR2329277A1 (de)
GB (1) GB1562823A (de)
NL (1) NL7609411A (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420479A (en) * 1982-04-08 1983-12-13 Eli Lilly And Company Olefinic benzimidazoles, formulations, and antiviral methods
US4434288A (en) * 1982-04-08 1984-02-28 Eli Lilly And Company Preparation of substituted 1-thiazinyl or 1-thiazolyl-2-aminobenzimidazoles
US4463181A (en) * 1982-04-08 1984-07-31 Eli Lilly And Company Process for removing sulfonyl groups from benzimidazole isomers
IL68297A (en) * 1982-04-08 1986-09-30 Lilly Co Eli Process for removing 1-sulfonyl groups from 2-amino-5(6)-substituted benzimidazoles
US4492708A (en) * 1982-09-27 1985-01-08 Eli Lilly And Company Antiviral benzimidazoles
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
US5693661A (en) * 1995-06-07 1997-12-02 Eli Lilly And Company Anti-viral compounds
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7649007B2 (en) * 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008021338A2 (en) * 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
WO2008021339A2 (en) * 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as pr modulators
WO2008021309A1 (en) * 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
US7538107B2 (en) 2006-08-15 2009-05-26 Wyeth Oxazinan-2-one derivatives useful as PR modulators
SG144809A1 (en) * 2007-01-11 2008-08-28 Millipore U K Ltd Benzimidazole compounds and their use as chromatographic ligands

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4842875B1 (de) * 1969-01-29 1973-12-14
US3749717A (en) * 1971-05-04 1973-07-31 Squibb & Sons Inc Thiazolinyl and thiazinyl derivatives of benzimidazoles
US3825537A (en) * 1972-02-28 1974-07-23 Squibb & Sons Inc 1-thiazolin-2-yl(or thiazin-2-yl)-2-aminobenzimidazoles and derivatives thereof
US4008243A (en) * 1975-11-19 1977-02-15 Eli Lilly And Company Antiviral thiazolinyl or thiazinyl benzimidazole esters

Also Published As

Publication number Publication date
DE2638553A1 (de) 1977-05-12
FR2329277A1 (fr) 1977-05-27
AU1698376A (en) 1978-02-23
CA1076582A (en) 1980-04-29
US4216313A (en) 1980-08-05
US4150028A (en) 1979-04-17
BE845642A (fr) 1977-02-28
DE2638553C2 (de) 1985-09-12
NL7609411A (nl) 1977-05-02
GB1562823A (en) 1980-03-19
ATA636476A (de) 1980-05-15
CH629203A5 (de) 1982-04-15
JPS5253861A (en) 1977-04-30
FR2329277B1 (de) 1978-11-17
AU509008B2 (en) 1980-04-17

Similar Documents

Publication Publication Date Title
AT365579B (de) Verfahren zur herstellung von neuen tetrahydroisochinoliniumverbindungen
AT360005B (de) Verfahren zur herstellung von neuen sulfonyl- benzimidazolderivaten
AT359657B (de) Verfahren zur herstellung von neuen prostan- derivaten
AT362085B (de) Verfahren zur herstellung von neuen 16- -dehydroandrostan-derivaten
AT344896B (de) Verfahren zur herstellung von neuen piperazinyliminorifamycinen
AT349633B (de) Verfahren zur herstellung von neuen dauno- saminylanthracylcinonen
AT344163B (de) Verfahren zur herstellung von neuen oxadiazolinon-derivaten
AT353956B (de) Verfahren zur herstellung von neuen cephalosporinantibiotika
AT360006B (de) Verfahren zur herstellung von neuen thiazolinylbenzimidazolderivaten
ATA585876A (de) Verfahren zur herstellung von neuen 2-benzimidazolylcarbamaten
AT347430B (de) Verfahren zur herstellung von neuen benzophenonderivaten
AT347453B (de) Verfahren zur herstellung von neuen 5-phenyl- oxazolidinon-2-derivaten
AT344150B (de) Verfahren zur herstellung von neuen cyclohexylphenylen
AT354650B (de) Verfahren zur herstellung von neuen bicyclo- heptenderivaten
AT349141B (de) Verfahren zur herstellung von neuen rifamyzin- verbindungen
AT357698B (de) Verfahren zur herstellung von neuen octapeptid- derivaten
AT353957B (de) Verfahren zur herstellung von neuen cephalos- porinderivaten
AT345801B (de) Verfahren zur herstellung von neuen 1-phenoxy- 2-acyloxy-3-amino-propanderivaten
AT342617B (de) Verfahren zur herstellung von neuen 1-methyl-3-alkyl-7-oxoalkylxanthinen
AT347967B (de) Verfahren zur herstellung von neuen biguaniden
ATA504978A (de) Verfahren zur herstellung von neuen thienothiazinderivaten
AT346355B (de) Verfahren zur herstellung von neuen 2- morpholinonderivaten
ATA127476A (de) Verfahren zur herstellung von neuen cephemderivaten
ATA572577A (de) Verfahren zur herstellung von neuen cyclohexylphenylen
ATA567778A (de) Verfahren zur herstellung von neuen 13-aethinyl- -steroiden

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee